The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants.
Antioxidants (Basel)
; 10(6)2021 May 31.
Article
en En
| MEDLINE
| ID: mdl-34072708
ABSTRACT
BACKGROUND:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the coronavirus disease of 2019 (COVID-19) that emerged in December 2019 in Wuhan, China, and rapidly spread worldwide, with a daily increase in confirmed cases and infection-related deaths. The World Health Organization declared a pandemic on the 11th of March 2020. COVID-19 presents flu-like symptoms that become severe in high-risk medically compromised subjects. The aim of this study was to perform an updated overview of the treatments and adjuvant protocols for COVID-19.METHODS:
A systematic literature search of databases was performed (MEDLINE PubMed, Google Scholar, UpToDate, Embase, and Web of Science) using the keywords "COVID-19", "2019-nCoV", "coronavirus" and "SARS-CoV-2" (date range 1 January 2019 to 31st October 2020), focused on clinical features and treatments.RESULTS:
The main treatments retrieved were antivirals, antimalarials, convalescent plasma, immunomodulators, corticosteroids, anticoagulants, and mesenchymal stem cells. Most of the described treatments may provide benefits to COVID-19 subjects, but no one protocol has definitively proven its efficacy.CONCLUSIONS:
While many efforts are being spent worldwide in research aimed at identifying early diagnostic methods and evidence-based effective treatments, mass vaccination is thought to be the best option against this disease in the near future.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Guideline
Idioma:
En
Revista:
Antioxidants (Basel)
Año:
2021
Tipo del documento:
Article
País de afiliación:
Italia